UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

American journal of hematology, 2021-01, Vol.96 (1), p.145-162

Tefferi, Ayalew

2021

Volltextzugriff (PDF)

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

Haematologica (Roma), 2024-07, Vol.109 (7), p.2060

2024

Volltextzugriff (PDF)

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Journal of clinical oncology, 2011-02, Vol.29 (4), p.392-397

2011

Volltextzugriff (PDF)

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target

Cell stem cell, 2017-06, Vol.20 (6), p.785-800.e8

2017

Volltextzugriff (PDF)

Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management

American journal of hematology, 2018-12, Vol.93 (12), p.1551-1560

Tefferi, Ayalew

2018

Volltextzugriff (PDF)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807

2012

Volltextzugriff (PDF)

What is pre‐fibrotic myelofibrosis and how should it be managed in 2018?

British journal of haematology, 2018-10, Vol.183 (1), p.23-34

2018

Volltextzugriff (PDF)

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Volltextzugriff (PDF)

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

Journal of clinical oncology, 2018-02, Vol.36 (4), p.310-318

2018

Volltextzugriff (PDF)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Volltextzugriff (PDF)

Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real‐world experience

British journal of haematology, 2022-08, Vol.198 (4), p.e54-e58

2022

Volltextzugriff (PDF)

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

The Lancet (British edition), 2023-01, Vol.401 (10373), p.269-280

2023

Volltextzugriff (PDF)

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

Mayo Clinic proceedings, 2012, Vol.87 (1), p.25-33

2012

Volltextzugriff (PDF)

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

The New England journal of medicine, 2010-09, Vol.363 (12), p.1117-1127

2010

Volltextzugriff (PDF)

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1356-1363

2011

Volltextzugriff (PDF)

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

Blood, 2016-03, Vol.127 (10), p.1317-1324

2016

Volltextzugriff (PDF)

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology, 2023-05, Vol.98 (5), p.801-821

Tefferi, Ayalew

2023

Volltextzugriff (PDF)

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Annals of hematology, 2018-03, Vol.97 (3), p.435-441

2018

Volltextzugriff (PDF)

A lasso and random forest model using flow cytometry data identifies primary myelofibrosis

Cytometry. Part B, Clinical cytometry, 2024-07, Vol.106 (4), p.272-281

2024

Volltextzugriff (PDF)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Leukemia, 2018-07, Vol.32 (7), p.1631-1642

2018

Volltextzugriff (PDF)

Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis

Nature cell biology, 2017-06, Vol.19 (6), p.677-688

2017

Volltextzugriff (PDF)

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Leukemia, 2017-12, Vol.31 (12), p.2726-2731

2017

Volltextzugriff (PDF)

Mutations and prognosis in primary myelofibrosis

Leukemia, 2013-09, Vol.27 (9), p.1861-1869

2013

Volltextzugriff (PDF)

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Blood, 2010-03, Vol.115 (9), p.1703-1708

2010

Volltextzugriff (PDF)

1 – 25 von 68.624

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62.089)
Mit Volltextzugriff
(55.311)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(60.940)
Medical Sciences
(60.927)
Hematologic And Hematopoietic Diseases
(60.619)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(60.430)
Humans
(59.137)
Science & Technology
(54.515)
Life Sciences & Biomedicine
(54.225)
Male
(32.307)
Female
(30.017)
Hematology
(25.548)
Middle Aged
(24.573)
Adult
(22.116)
Oncology
(21.105)
Aged
(19.944)
Adolescent
(9.966)
Child
(7.937)
Prognosis
(7.810)
Aged, 80 And Over
(7.406)
Tumors
(6.920)
Leukemia
(6.341)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(60.558)
EZB Electronic Journals Library
(39.685)
Journals@Ovid Ovid Full Text
(35.610)
Single Journals
(23.664)
IngentaConnect Journals
(23.387)
Wiley Online Library - AutoHoldings Journals
(15.720)
Wiley Online Library Full Collection 2018
(14.635)
Elsevier ScienceDirect Journals Complete
(10.693)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(8.360)
IngentaConnect Journals
(8.353)
Nature
(7.153)
Nexis Uni
(6.320)
Springer Journals
(5.294)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(4.595)
Oxford Journals Online Current
(2.773)
Springer Book Series
(2.120)
Oxford Journals 2020 Medicine
(1.874)
Taylor & Francis Journals
(1.264)
Taylor & Francis:Master (3349 titles)
(1.215)
Taylor & Francis
(1.211)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(7.350)
British Journal Of Haematology
(4.698)
Leukemia
(4.401)
Cancer
(2.060)
Cancer Genetics And Cytogenetics
(1.764)
Haematologica
(1.661)
American Journal Of Hematology
(1.651)
Leukemia Research
(1.576)
International Journal Of Hematology
(1.543)
Journal Of Clinical Oncology
(1.389)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)
... seit 90 Tagen
(76)

Menü

Weitere Dienste

Einstellungen

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target

Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

What is pre‐fibrotic myelofibrosis and how should it be managed in 2018?

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real‐world experience

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

A lasso and random forest model using flow cytometry data identifies primary myelofibrosis

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Mutations and prognosis in primary myelofibrosis

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Suchergebnisse filtern